Making Healthcare More Accessible in Asia

Zuellig Pharma provides world-class pharmaceutical distribution, digital and commercial services to support the evolving healthcare needs in the region.

Unlock the potential of Asia with Zuellig Pharma's unique healthcare solutions.

Select Marketdropdown carat
  • Australia
  • Brunei
  • Cambodia
  • China
  • Hong Kong - Macau
  • India
  • Japan
  • Korea
  • Malaysia
  • Philippines
  • Singapore
  • Taiwan
  • Thailand
  • Vietnam
  • Indonesia
Zuellig Pharma's depot in South Australia is a TGA-licensed facility that is approximately 1,300 sq.m. The facility has managed over 1,000 clinical trials since its foundation and currently manages more than 350 clinical trials.

Opportunities

  • Clinical Trial Supplies Market to reach USD 5.7B by 2027.
  • Healthcare CROs market in Australia and New Zealand valued at USD 1B in 2022.
  • CAGR of 11.5% expected for healthcare CROs market from 2023-2030.
  • Virtual clinical trials adoption to drive CRO industry growth in the region.
  • Clinical trials in Australia offer R&D tax advantages and cost efficiency, driving industry growth.

Capabilities

  • Global depot & cold chain logistics for reliable healthcare delivery.
  • Sophisticated temperature-controlled. infrastructure adhering to industry standards (GDP, GMP, CSV, HSE).
  • Smart Sourcing Solution for unparalleled access to medicine, incl. controlled drugs.
  • Specialised cold chain for temperature-sensitive materials.
  • Innovative patient-centric approach to clinical trials with depot-to-patient solutions.
Zuellig Pharma's depot in South Australia is a TGA-licensed facility that is approximately 1,300 sq.m. The facility has managed over 1,000 clinical trials since its foundation and currently manages more than 350 clinical trials.

Opportunities

  • Brunei's government tenders make up 70% of healthcare business.
  • Thriving retail business with potential for chain pharmacy expansion.
  • Growing oncology opportunities in public and private sectors.
  • Potential for Brunei's Ministry to plan, promote, and develop medical tourism.
  • Increasing demand for health and medical services due to ageing population.

Capabilities

  • Leading healthcare provider in Brunei with 36 years of experience as only foreign invested company.
  • Largest distributor and market leader, serving 9 of top 10 pharma clients in Brunei.
  • Excellent RA capabilities, holding market authorisation for 25% of registered medicinal products with MOH.
  • Innovative, automated warehouse system handles 80% of biologics and cold chain products in Brunei.
  • Robust tender management team with excellent track record in handling MOH tenders at scale.
Zuellig Pharma's Cambodia facilities offer a newly-built distribution centre with an over 6,300 sq.m. warehouse and 1,200 sq.m. mezzanine for healthcare products, including 6,400 pallets in 6-high racking and 240 cold room storage pallets. With 90% coverage of ethical, pharmacy, and modern trade, we serve over 10,000 healthcare customers nationwide, including hospitals, clinics, and pharmacies, through 200 sales and marketing representatives. Our quality of work is recognised with certifications such as GDSP, GMP, GDPMDD, and ISO 9001:2015.

Opportunities

  • Expansion of universal healthcare boosts medical services utilisation.
  • NGOs continue to provide essential medicines.
  • Basic medicines are vital due to regional production and low domestic manufacturing.
  • Total pharmaceutical sales reached USD 386M in 2022 with per capita spending at USD 23.
  • Pharmaceutical consumption rises to treat growing prevalence of chronic lifestyle diseases.

Capabilities

  • Zuellig Pharma has 20 years' experience as healthcare provider in Cambodia, serving four top 10 Pharma clients.
  • Largest cold-room facility in Cambodia with state-of-the-art infrastructure for healthcare.
  • Proven cold chain tech maintains optimal quality during delivery.
  • Passive packaging with unique thermal isolation chamber system.
  • Patient-centric affordability and adherence programs.
  • Custom mobile app for client program admin, enrolments, and updates.
Zuellig Pharma China's Beijing facility, with 20 years of clinical supply experience, is GDP/GMP compliant and a trusted partner for various clients in clinical trials, including pharmaceutical companies, CROs, CMOs, biopharmaceutical firms, medical device companies, and diagnostic firms.

Opportunities

  • China's pharmaceutical market to reach USD 161.8B by 2023, accounting for 30% of global market.
  • Ageing population and increased life expectancy driving rising demand for healthcare in China.
  • Pharma sales in China projected to grow by 4.04% in 2022 and 3.58% in 2023.
  • Chinese government promoting industry consolidation to regulate and control drug pricing.
  • China imports biotechnology pharmaceuticals to meet growing domestic demand.

Capabilities

  • Reliable global cold chain logistics network
  • Sophisticated GDSP and GMP temperature-controlled facilities
  • Smart sourcing solution for unparalleled medicine access
  • Specialised cold chain solutions for sensitive materials in clinical storage
  • Central distribution service for global studies
  • Tailored repackaging services with multilingual labels
Zuellig Pharma has two warehouses in Hong Kong spanning over 48,000 sq.m., offering air-conditioned storage for 24,000 pallets and cold chain storage for 800 pallets. We serve 10,000+ healthcare customers, including hospitals, clinics, dentists, and drug stores. Zuellig Pharma moves 48,000 cubic meters of products annually and has won awards such as the HR Distinction Awards - Excellence in Employee Wellbeing and Occupational Health Award - Excellence Award of Joyful@Healthy Workplace Best Practices Award.

Opportunities

  • China's pharmaceutical market to reach USD 161.8B by 2023, accounting for 30% of global market.
  • Ageing population and increased life expectancy driving rising demand for healthcare in China.
  • Pharma sales in China projected to grow by 4.04% in 2022 and 3.58% in 2023.
  • Chinese government promoting industry consolidation to regulate and control drug pricing.
  • China imports biotechnology pharmaceuticals to meet growing domestic demand.

Capabilities

  • Reliable global cold chain logistics network
  • Sophisticated GDSP and GMP temperature-controlled facilities
  • Smart sourcing solution for unparalleled medicine access
  • Specialised cold chain solutions for sensitive materials in clinical storage
  • Central distribution service for global studies
  • Tailored repackaging services with multilingual labels
Zuellig Pharma's facility in India is strategically-located in Mumbai to ensure that products and services are made available with the shortest leadtime. Covering over 1,530 sq.m., the facility offers one-stop solutions for every client's clinical trial needs, including a global depot and cold chain logistics network with temperature-controlled infrastructure and GDSP and GMP facilities for fast product and service availability. India is a cost-efficient and profitable market for major pharma, and biotech companies, as well as CROs, with local models meeting country standards.

Opportunities

  • China's pharmaceutical market to reach USD 161.8B by 2023, accounting for 30% of global market.
  • Ageing population and increased life expectancy driving rising demand for healthcare in China.
  • Pharma sales in China projected to grow by 4.04% in 2022 and 3.58% in 2023.
  • Chinese government promoting industry consolidation to regulate and control drug pricing.
  • China imports biotechnology pharmaceuticals to meet growing domestic demand.

Capabilities

  • Reliable global cold chain logistics network
  • Sophisticated GDSP and GMP temperature-controlled facilities
  • Smart sourcing solution for unparalleled medicine access
  • Specialised cold chain solutions for sensitive materials in clinical storage
  • Central distribution service for global studies
  • Tailored repackaging services with multilingual labels
Zuellig Pharma has an impressive partner depot facility in Japan, covering a total area of around 1.2 million sq.m., out of which 300,000 sq.m. are solely dedicated to pharmaceutical handling. Apart from its extensive size and specialisation, the partner depot also prioritises sustainability, evident through the installation of solar power generation systems and nighttime heat storage type air conditioning systems in all its offices.

Opportunities

  • Japan's ¥10-trillion (USD 75B) national endowment fund signals growth in healthcare industry.
  • Japan accounts for 4.7% of global clinical trial activity in 2022.
  • Japan's developed healthcare system and ageing population increase demand for new treatments.
  • Sakigake package accelerates drug and device approvals in Japan.
  • Japanese Ministry of Health promotes innovation in pharmaceutical manufacturing.

Capabilities

  • Partner depot in Japan obtained Green Management Certificate.
  • Global logistics network with depots and cold chain infrastructure.
  • Facilities comply with GDSP and GMP standards and offer advanced temperature control technology for cold chain solutions.
  • Smart Sourcing Solution for exclusive access to medicines and controlled drugs.
  • High standards of quality maintained, meeting GDP, GMP, CSV, and HSE requirements.
Zuellig Pharma's Korea facilities comprise 12 warehouses and a team of 150 sales and marketing representatives serving over 36,000 healthcare customers nationwide. We have received various accolades and certifications for sustainability, transparency in pharmaceutical distribution, and industry leadership.

Opportunities

  • Strong healthcare system and popular medical tourism market.
  • Booming digital health sector with patient-focused innovation.
  • High purchasing power and one of the highest GDP per capita in APAC region.
  • Rapidly expanding pharmaceutical industry with USD 17.9B reach and 9.6% CAGR in 2021.
  • Thriving medical device industry with USD 7.9B reach and 10.6% CAGR in 2021, ranking 9th globally.
  • Ageing population with growing healthcare demands.
  • Increasingly recognised as a key destination for clinical trials in the Asian pharmaceutical market.

Capabilities

  • 25 years experience as a healthcare service provider in South Korea.
  • Operate South Korea’s largest cold-room facility.
  • South Korea’s largest specialty and vaccine distributor, and Asia’s clinical logistics leader.
  • Preferred go-to commercialisation partner for high compliance standards and transparency.
  • Customised technology solutions for eCommerce, block-chain, and business analytics.
Zuellig Pharma's Malaysia facilities include a main warehouse in Bukit Jelutong and an approximately 7,000 sq.m. warehouse for dialysis solutions, medical supplies, and surgical lenses. With two branch offices and a branch warehouse, Zuellig Pharma has 100% coverage of hospitals, clinics, and pharmacies with over 15,000 customers across Malaysia. We have won numerous awards for quality and certifications.

Opportunities

  • National health insurance system reduces healthcare expenses and improves accessibility.
  • Companies Act encourages foreign investment in the pharmaceutical sector.
  • National efforts combat malnutrition, undernutrition, and obesity through health and educational programs.
  • International aid packages boost local health facilities in combating COVID-19.

Capabilities

  • Zuellig Pharma has 8 years of experience in Myanmar, serving 6 out of the top 10 pharma clients.
  • Our top-notch cold-room facilities use advanced infrastructure.
  • Our cold chain transport tech and packaging use thermal isolation chambers for quality maintenance.
  • We provide patient-centric solutions for affordability and adherence.
  • Custom mobile apps are available for client program administration and real-time updates.
Zuellig Pharma in the Philippines has seven distribution warehouses covering over 59,000 sq.m. of distribution centre space for pharma, consumer, medical devices, and diagnostics products. We have over 1,700 employees nationwide and have distributed to over 19,000 physicians, 700 private hospitals, 7,000 chain drug stores, and more. We have been recognised for our quality of work and sustainability efforts.

Opportunities

  • Ophthalmology agency business shows consistent growth building on B&L.
  • Diagnostic and consumable business is rapidly growing, currently 53% SOB in MDI.
  • Animal health business is rapidly growing, especially in the pet segment.
  • Capitalising on client relationships to drive commercialisation initiatives.
  • Potential to improve awareness and utilisation of value-added services (VAS) for higher operating revenue and client conversion.

Capabilities

  • Over 100 years of experience in pharma distribution in the Philippines.
  • 100% coverage of hospitals, pharma, modern trade accounts & 50k+ customers nationwide.
  • Strong market presence in 86 therapeutic classes.
  • Wide range of services incl. Repackaging, Samples Distribution, Product Destruction & Trade Marketing (CHC).
  • Innovative tech solutions incl. eZHealth, eZRx & e-Commerce solutions.
  • Patient-centric programs for adherence, access & affordability.
Zuellig Pharma's Singapore facilities cover over 44,000 sq.m. across three warehouses and serve over 6,000 healthcare customers with extensive ethical, pharmacy, and modern trade coverage. We have received various accolades and certifications, such as the HR Asia Best Companies to Work (2020) for Singapore, IDC Future Enterprise Awards (2022), and National Awards (COVID-19) 2022 recipient for President's Certificate of Commendation for Singapore.

Opportunities

  • National health insurance system reduces healthcare expenses and improves accessibility.
  • Companies Act encourages foreign investment in the pharmaceutical sector.
  • National efforts combat malnutrition, undernutrition, and obesity through health and educational programs.
  • International aid packages boost local health facilities in combating COVID-19.

Capabilities

  • Zuellig Pharma has 8 years of experience in Myanmar, serving 6 out of the top 10 pharma clients.
  • Our top-notch cold-room facilities use advanced infrastructure.
  • Our cold chain transport tech and packaging use thermal isolation chambers for quality maintenance.
  • We provide patient-centric solutions for affordability and adherence.
  • Custom mobile apps are available for client program administration and real-time updates.
Zuellig Pharma in Taiwan boasts five warehouses spanning over 65, 000 sq.m. and catering to pharmaceuticals, consumer goods, and medical devices. We offer 100% coverage of ethical, pharmacy, and modern trade services, serving 20,000+ healthcare customers with over 200 sales and marketing representatives. We have received accolades like the National Healthcare Quality Award and National Biotechnology and Medicine Care Quality Award.

Opportunities

  • National health insurance system reduces healthcare expenses and improves accessibility.
  • Companies Act encourages foreign investment in the pharmaceutical sector.
  • National efforts combat malnutrition, undernutrition, and obesity through health and educational programs.
  • International aid packages boost local health facilities in combating COVID-19.

Capabilities

  • Zuellig Pharma has 8 years of experience in Myanmar, serving 6 out of the top 10 pharma clients.
  • Our top-notch cold-room facilities use advanced infrastructure.
  • Our cold chain transport tech and packaging use thermal isolation chambers for quality maintenance.
  • We provide patient-centric solutions for affordability and adherence.
  • Custom mobile apps are available for client program administration and real-time updates.
Zuellig Pharma runs four warehouses in Thailand, with 56,400 pallet storage space and a full range of temperature-controlled cold chain rooms for various products. We offer 98% customer coverage of ethical, pharmacy, and OTC, serving over 22,000 healthcare customers with 500 sales and marketing representatives, and have distributed 87% of vaccines to date. We have received numerous accolades, including nine awards at the 2022 TCCTA Contact Center Awards.

Opportunities

  • National health insurance system reduces healthcare expenses and improves accessibility.
  • Companies Act encourages foreign investment in the pharmaceutical sector.
  • National efforts combat malnutrition, undernutrition, and obesity through health and educational programs.
  • International aid packages boost local health facilities in combating COVID-19.

Capabilities

  • Zuellig Pharma has 8 years of experience in Myanmar, serving 6 out of the top 10 pharma clients.
  • Our top-notch cold-room facilities use advanced infrastructure.
  • Our cold chain transport tech and packaging use thermal isolation chambers for quality maintenance.
  • We provide patient-centric solutions for affordability and adherence.
  • Custom mobile apps are available for client program administration and real-time updates.
Zuellig Pharma's Vietnam facilities comprise five warehouses with over 23,000 AC pallets and 1,700 CC pallets, catering to various healthcare products. We provide 100% coverage across all medical channels, serving over 60,000 healthcare customers. Our certifications include GDP, GCP, GMP, GSP and GSDP, GDPMD, ISMS, and ISO.

Opportunities

  • National health insurance system reduces healthcare expenses and improves accessibility.
  • Companies Act encourages foreign investment in the pharmaceutical sector.
  • National efforts combat malnutrition, undernutrition, and obesity through health and educational programs.
  • International aid packages boost local health facilities in combating COVID-19.

Capabilities

  • Zuellig Pharma has 8 years of experience in Myanmar, serving 6 out of the top 10 pharma clients.
  • Our top-notch cold-room facilities use advanced infrastructure.
  • Our cold chain transport tech and packaging use thermal isolation chambers for quality maintenance.
  • We provide patient-centric solutions for affordability and adherence.
  • Custom mobile apps are available for client program administration and real-time updates.
Zuellig Pharma provides complete coverage of ethical, pharmacy, and modern trade products in Indonesia, serving over 26,000 direct outlets with over 2,800 trained employees, 25 warehouses, 4 sales offices, and 8 APL partners' locations. The team has amassed numerous accolades, such as the HR Asia Best Companies to Work for in Asia and CNBC Indonesia Outstanding Company in Sustainability-Community Initiative awards.

Opportunities

  • China's pharmaceutical market to reach USD 161.8B by 2023, accounting for 30% of global market.
  • Ageing population and increased life expectancy driving rising demand for healthcare in China.
  • Pharma sales in China projected to grow by 4.04% in 2022 and 3.58% in 2023.
  • Chinese government promoting industry consolidation to regulate and control drug pricing.
  • China imports biotechnology pharmaceuticals to meet growing domestic demand.

Capabilities

  • Reliable global cold chain logistics network
  • Sophisticated GDSP and GMP temperature-controlled facilities
  • Smart sourcing solution for unparalleled medicine access
  • Specialised cold chain solutions for sensitive materials in clinical storage
  • Central distribution service for global studies
  • Tailored repackaging services with multilingual labels
image

Get in Touch

Contact us today to discuss new business opportunities, partnerships, customer service, or any other inquiries you may have.
Contact Us

AwardSection

JSS component is missing React implementation. See the developer console for more information.

NewsandQuickLinks

JSS component is missing React implementation. See the developer console for more information.